Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Limited (Baird Medical) operates as a specialized healthcare innovator focused on thyroid-related diseases, aiming to transform traditional thyroid treatment through intelligent, non-invasive solutions. The company's mission is to build an ecosystem spanning early screening, diagnosis, robotic-assisted ablation, and post-treatment care. Baird Medical's core strengths include the successful development and commercialization of its thyroid microwave ablation system and an active R&D pipeline featuring AI-integrated robotic systems. The company ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022, and was the third largest overall microwave ablation medical device provider in the PRC by sales revenue in the same year ¹.

The core business model of Baird Medical primarily involves the design, development, manufacturing, and sale of its proprietary microwave ablation (MWA) medical devices, with sales of other medical devices constituting a minor portion of revenue. In 2025, 2024, and 2023, sales of proprietary MWA medical devices represented 100.0%, 100.0%, and 98.4% of total revenue, respectively, while sales of other medical devices accounted for nil, nil, and 1.6% of total revenue, respectively ². The company's products are ultimately sold to hospitals through direct sales, deliverers, or distributors. As of December 31, 2025, Baird Medical's products were procured by approximately 614 hospitals in China, including approximately 329 Grade III hospitals ³.

Baird Medical's product offerings include microwave ablation therapeutic apparatus and microwave ablation needles. The company produces five models of proprietary microwave ablation therapeutic apparatus and has sold more than 1,300 units of these devices as of the date of the annual report ⁴. For microwave ablation needles, which are non-reusable consumables, approximately 100,000 single-use needles have been sold as of the date of the annual report ⁵. The company holds four Class III registration certificates for its MWA therapeutic instrument and accessories, and disposable MWA needles, with validity periods extending to February 5, 2028, July 12, 2028, March 18, 2029, and December 3, 2028, respectively ⁶. Additionally, its MWA apparatus and needles have received approval from the FDA and Indonesia Drug Administration for soft tissue ablation ⁷.

For the fiscal year ended December 31, 2025, Baird Medical reported total revenues of $22,537,016 ⁸, a decrease of 39.2% from $37,037,108 in 2024 ⁹. Cost of revenues decreased by 16.7% from $4,383,363 in 2024 to $3,653,278 in 2025 ¹⁰. Gross profit for 2025 was $18,883,738 ¹¹, down from $32,653,745 in 2024 ¹², resulting in a gross profit margin of 83.8% in 2025 compared to 88.2% in 2024 ¹³. The company incurred a net loss of $27,541,124 in 2025 ¹⁴, a significant shift from a net income of $12,598,098 in 2024 ¹⁵. Diluted earnings per common share were $(0.98) in 2025, compared to $0.57 in 2024 ¹⁶. Cash and equivalents are not explicitly stated as a consolidated figure in the provided text. Total debt is not explicitly stated as a consolidated figure.

Year-over-year, total revenues decreased by 39.2% from $37,037,108 in 2024 to $22,537,016 in 2025 ¹⁷. This was primarily driven by a decrease in demand and sales of MWA devices, with revenue from direct customers falling from $19,817,099 in 2024 to $4,129,425 in 2025 ¹⁸. Conversely, revenue from distributors increased from $17,220,009 in 2024 to $18,407,591 in 2025 ¹⁹, mainly due to an increase in selling price, partially offset by changes in sales volume. Gross profit margin contracted from 88.2% in 2024 to 83.8% in 2025 ²⁰. Operating expenses significantly increased, with selling and marketing expenses rising from $4,061,116 in 2024 to $10,264,507 in 2025 ²¹, and research and development expenses surging from $6,174,365 in 2024 to $20,131,012 in 2025 ²². General and administrative expenses also increased from $7,103,226 in 2024 to $14,119,024 in 2025 ²³. These increases in operating expenses, particularly R&D, contributed to the shift from operating income of $15,315,038 in 2024 to an operating loss of $25,630,805 in 2025 ²⁴.

During the reported period, Baird Medical continued its focus on R&D, increasing expenditures significantly. The company incurred research and development expenses of $20,131,012 in 2025, up from $6,174,365 in 2024 ²⁵, primarily due to increased FDA certification fees, CE Marking fees, and R&D expenditures on AI ablation systems and equipment ²⁶. The company also obtained an updated medical device production license on October 16, 2023, in accordance with the 2022 Supervisory and Administrative Measures for Production, after applying to add "Class II: 14-01 Injection and Puncture Instruments" to its production scope ²⁷. In November 2024, the company was subject to a confiscation of sales revenue of approximately RMB4.2 million and an administrative penalty of approximately RMB434,000 due to a failure to renew its previous manufacture license within the prescribed time period in 2021 ²⁸.

Baird Medical's management anticipates continued efforts in research and development, particularly in expanding its product pipeline. The company has five types of pipeline products that require product registration testing to demonstrate safety and effectiveness for Class III medical devices ²⁹. Additionally, Baird Medical has engaged Nanjing Huitong Medical Technology Co., Ltd. to assist with applications for Class III medical device registration certificates specifically approved for the treatment of liver cancer and thyroid nodules for all existing models of its Class II microwave ablation needles, and to expand indications on its Class III medical device registration certificate to include breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, with all such indications expected to be obtained by 2026 ³⁰.

The company's operational outlook includes a focus on the research and development, manufacturing, and sales of microwave ablation products, with a specific emphasis on the development of AI surgical machines and other minimally invasive medical devices for surgical procedures ³¹. This strategic shift is driven by the market potential of microwave ablation products and past sales performance. The company's gross profit margin, which was 83.8% in 2025 ³², may not be sustainable due to potential low-margin sales, competitive strategies, increasing raw material costs, and expanding sales and distribution network costs ³³.

Regarding capital allocation, Baird Medical's research and development expenses increased significantly to $20,131,012 in 2025 ³⁴, primarily driven by FDA certification fees, CE Marking fees, and R&D expenditures on AI ablation systems and equipment ³⁵. The company expects to issue additional share capital in the future, which will result in dilution to existing shareholders, in connection with financings, acquisitions, investments, and its equity incentive plans ³⁶. The 2024 Equity Incentive Plan has an evergreen feature, with the share reserve automatically increasing by 1,229,381 Ordinary Shares effective January 1, 2026 ³⁷. Baird Medical does not intend to pay any cash dividends before it becomes profitable, which may not occur in the foreseeable future ³⁸.

Management has flagged several structural headwinds and execution risks. The company's historical high gross profit margin may not be sustainable due to market changes, regulatory environment shifts, sales network management challenges, and intensified competition ³⁹. There is also uncertainty regarding the timely and successful completion of product registration testing and clinical trials for its pipeline products, which could delay or deny regulatory approvals from the NMPA ⁴⁰. Furthermore, the company's products have not yet been covered by centralized national procurement, but if they are in the future, the price of these products may decrease, potentially harming profitability if sales volume increases do not fully compensate for the price reduction ⁴¹.

Baird Medical faces several material risks, including significant customer concentration, with two largest customers accounting for 23.3% and 12.0% of total revenue in 2025 ⁴². The company also has supplier concentration, with two major suppliers contributing 46.0% and 29.6% of total cost of revenues in 2025 ⁴³. Regulatory risks are substantial, including the potential inability to obtain, maintain, or renew necessary regulatory filings and registration certificates for microwave medical devices in a timely manner, or at all, from the NMPA ⁴⁴. The company has a history of regulatory non-compliance, having been fined approximately RMB434,000 and subjected to a confiscation of sales revenue of approximately RMB4.2 million in November 2024 for failing to renew a manufacture license in 2021 ⁴⁵. Furthermore, the company does not maintain product liability insurance, leaving it exposed to potential claims without coverage ⁴⁶. Geopolitical risks include uncertainties in the interpretation and enforcement of PRC laws, rules, and regulations, which can change quickly with little advance notice ⁴⁷. The company is also subject to potential delisting from Nasdaq under the HFCAA if the PCAOB is unable to inspect its auditors in China for two consecutive years ⁴⁸. Economic risks include the potential for global or Chinese economic slowdowns, which could reduce demand for products, and the impact of trade policies, such as the additional 20% duty on Chinese imports imposed by the United States in February and March 2025, and retaliatory tariffs from China ⁴⁹.

Management's overall tone emphasizes Baird Medical's commitment to innovation in thyroid-related diseases and its strategic focus on developing intelligent, non-invasive solutions. They highlight the company's established position as a leader in the PRC microwave ablation market for thyroid nodules and breast lumps, and its third-largest standing overall in the PRC microwave ablation medical device market in 2022 ⁵⁰. Key strategic priorities for the period ahead include continued significant investment in research and development, particularly in AI ablation systems and equipment, as evidenced by the substantial increase in R&D expenses to $20,131,012 in 2025 ⁵¹. Management also stresses the importance of expanding product indications, with applications for Class III medical device registration certificates for additional diseases expected by 2026 ⁵². Furthermore, the company aims to maintain and expand its strategically managed network with hospitals and medical device distributors, which has already led to an increase in the number of hospitals procuring its products to 614 in 2025 ⁵³.